MTOR and cholangiocarcinoma: We chose Infigratinib, a selective FGFR1-3 inhibitor to target FGFR signaling (FDA-approved for treatment of cholangiocarcinoma with an FGFR2 fusion), and Everolimus which inhibits the formation of the mTOR complex, for testing in combination with BCL2i.